ProfileGDS5678 / 1449821_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 92% 91% 92% 94% 93% 92% 93% 93% 93% 92% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8527993
GSM967853U87-EV human glioblastoma xenograft - Control 27.924193
GSM967854U87-EV human glioblastoma xenograft - Control 37.705992
GSM967855U87-EV human glioblastoma xenograft - Control 47.6562791
GSM967856U87-EV human glioblastoma xenograft - Control 57.7618692
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.9813594
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.774393
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5530992
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.7598393
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7956593
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7771693
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.7993292
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6768392
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.786693